{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    4,
    5,
    8,
    39,
    40
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 0.8,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_6",
        "affectedSection": "Global - Versioning",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Incorporation of Nonsubstantial Amendment 6 into the protocol version 5.1."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_6",
        "affectedSection": "Section 2.2.1 - Study Design",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated survival follow-up and Quality of Life (QoL) data collection requirements following the final Overall Survival (OS) analysis."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_6",
        "affectedSection": "Section 12.7 - Clinical Study Continuity",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added provisions for study continuity and transition of subjects to other Astellas-sponsored studies."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_6",
        "reasonText": "To define the completion of survival follow-up and QoL assessments once the target number of OS events is reached.",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_6",
        "reasonText": "To provide a mechanism for subjects receiving clinical benefit to continue treatment after study termination.",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_6",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "2.2.1",
        "afterText": "Once the final number of events has been reached to trigger the final OS analysis, survival follow-up will be considered complete and subjects will be discontinued from long term follow-up.",
        "summary": "Clarified the end of long-term survival follow-up."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_6",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "2.2.1",
        "afterText": "Once the final number of events has been reached to trigger the final OS analysis, sites will no longer be required to collect EQ-5D-5L, QLQ-PR25, FACT-P for QoL and BPI-SF.",
        "summary": "Discontinued QoL and pain assessment collection after final OS analysis."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_6",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "2.2.1",
        "beforeText": "At the time of primary endpoint analysis... subjects may be asked to continue their open-label treatment in another Astellas-sponsored study.",
        "afterText": "Subjects who are continuing to receive clinical benefit from treatment with enzalutamide after the OS analysis data cutoff or at study termination... may continue their open-label treatment in another Astellas-sponsored study.",
        "summary": "Updated criteria for transitioning subjects to open-label extension or other studies based on clinical benefit."
      }
    ],
    "summary": {
      "impactCount": 3,
      "reasonCount": 2,
      "changeCount": 3
    }
  }
}